Kunle Odunsi
Roswell Park Cancer Institute EDDOP · Roswell Park Cancer Institute · Cancer Immunotherapy Trials Network
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Kunle Odunsi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:34 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT03206047 · Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerNational Cancer Institute (NCI) · terminated · Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma · principal investigator
- Ph1NCT02833506 · Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal CancerRoswell Park Cancer Institute · withdrawn · Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma · principal investigator
- Early Ph1NCT02042430 · Epacadostat Before Surgery in Treating Patients With Newly Diagnosed Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerNational Cancer Institute (NCI) · completed · Stage III Fallopian Tube Cancer AJCC v7, Stage III Ovarian Cancer AJCC v6 and v7, Stage III Primary Peritoneal Cancer AJCC v7 · principal investigator
- Ph1NCT02015416 · A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic CancerImmune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · completed · Melanoma, Ovarian Cancer, Sarcoma · principal investigator
- Ph1/Ph2NCT01982487 · Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in RemissionRoswell Park Cancer Institute · withdrawn · Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer · principal investigator
- Ph1NCT01673217 · Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal CancerRoswell Park Cancer Institute · completed · Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer · principal investigator
- Ph1/Ph2NCT01567891 · CT Antigen TCR-redirected T Cells for Ovarian Cancer.Adaptimmune · completed · Ovarian Cancer · study chair
- Ph1NCT01536054 · Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity CancerRoswell Park Cancer Institute · completed · Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer · principal investigator
- Ph1NCT01522820 · Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid TumorsRoswell Park Cancer Institute · completed · Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Anaplastic Oligodendroglioma · principal investigator
- Ph1NCT00803569 · Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancersLudwig Institute for Cancer Research · completed · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer · study chair
- Ph2NCT00112957 · Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal CancerLudwig Institute for Cancer Research · completed · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:34 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 2 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Enhancing Personalized Care in Ovarian Cancer Through Prospective Exercise Interventions and AI-Driven Data IntegrationP50CA159981 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · fiscal years 2013 to 2025 · $198,657 awarded in 2025Same name and institution; not confirmed by an ID
- Immuno-Oncology Translation Network: Data Management and Resource-Sharing Center at RPCIU24CA232979 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · fiscal years 2018 to 2021 · $841,000 awarded in 2021Same name and institution; not confirmed by an ID
- Post-doctoral research training in surgical oncologyT32CA108456 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · fiscal years 2015 to 2019 · $211,120 awarded in 2019Same name and institution; not confirmed by an ID
- Reprograming the tumor microenvironment to overcome multiple primary and acquired immune resistance mechanisms in ovarian cancerU01CA233085 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · fiscal years 2019 · $802,002 awarded in 2019Same name and institution; not confirmed by an ID
- mTOR inhibition for generating memory T cells to enhance ovarian tumor immunityR01CA158318 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · fiscal years 2011 to 2015 · $347,118 awarded in 2015Grant number is on one of their registry trials
- Ovarian Cancer Detection Using H-NMR_Based MetabonomicsR21CA106949 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · fiscal years 2005 to 2006 · $181,177 awarded in 2006Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Administrative CoreP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Dale Henry · fiscal years 2019 to 2026
- Cancer Center AdministrationP30CA015704 · NCI · FRED HUTCHINSON CANCER CENTER · PI WENDY LAW · fiscal years 2019 to 2026Named on NCT02042430
- U01CA154967RePORTER returned no project for this number; it is shown as the registry gives it.Named on NCT02042430
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:34 UTC. The ranking covers the 200 most relevant of 20 PubMed records, and a shared surname and initials can bring in a namesake. All 20 on PubMed
- Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.N Engl J Med · 20126,565 citationsRCR 174.5
- Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.Proc Natl Acad Sci U S A · 2007215 citationsRCR 3.9
- 192 citationsRCR 10.5
- Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial.Nat Med · 2023183 citationsRCR 13.0
- Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients.Proc Natl Acad Sci U S A · 2012161 citationsRCR 3.8
- Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer.Cancer Immunol Res · 2014159 citationsRCR 4.1
- NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome.Clin Cancer Res · 201884 citationsRCR 2.6
- A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.Clin Cancer Res · 201775 citationsRCR 2.0
- Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.Clin Cancer Res · 200654 citationsRCR 1.1
- 52 citationsRCR 1.7